Specifically, high levels of IL-6 in the serum of MM patients: i) directly correlate with tumor burden and disease severity [13, 14]; ii) promote MM progression [15, 16] through pleiotropic effects on cell proliferation, survival, migration and resistance to conventional chemotherapy; and iii) may represent a negative prognostic factor [17–19]. Here, IL6 is linked to neoplasm.